XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference
October 29 2007 - 4:09AM
PR Newswire (US)
NEW YORK, October 29 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced
today that Ron Bentsur, the Company's Chief Executive Officer, is
scheduled to present at the Acumen BioFin Rodman & Renshaw 9th
Annual Health Care Conference. Mr. Bentsur will present an overview
of the Company including a discussion of Bicifadine, the Company's
late-stage clinical compound for the treatment of neuropathic pain.
Mr. Bentsur's presentation will take place on Monday, November 5,
2007 at 8:50 am EST at the New York Palace Hotel in New York City.
A live webcast of the presentation will be available at:
http://www.wsw.com/webcast/rrshq12/xtlb. An archived version of the
webcast will be available following the conclusion of the live
presentation. About XTL Biopharmaceuticals Ltd. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C.
XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of diabetic neuropathic pain.
XTL is also developing several novel pre-clinical hepatitis C small
molecule inhibitors. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact
Ron Bentsur, Chief Executive Officer Tel: +1-845-267-0707 ext. 225
DATASOURCE: XTL Biopharmaceuticals Ltd CONTACT: Contact: Ron
Bentsur, Chief Executive Officer, Tel: +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024